Footman Katharine, Scott Rachel, Taleb Fahmida, Dijkerman Sally, Nuremowla Sadid, Reiss Kate, Church Kathryn
Health Systems Department, Marie Stopes International, 1 Conway Street, London W1T 6LP, UK.
London, UK.
Contraception. 2018 Feb;97(2):152-159. doi: 10.1016/j.contraception.2017.08.002. Epub 2017 Aug 17.
To assess the feasibility of following up women who purchase mifepristone+misoprostol or misoprostol-only from pharmacies in order to measure the safety and effectiveness of self-administration of menstrual regulation.
A prospective cohort study followed women purchasing mifepristone+misoprostol or misoprostol-only from pharmacies in Bangladesh. Participants were recruited by pharmacy workers either in person or indirectly via the purchaser of the drugs. End users were contacted by phone 2 weeks after recruitment, screened and interviewed.
Study recruitment rates by pharmacy workers were low (30%, 109 of 642 women informed about the study), but 2-week follow-up rates were high (87%). Of the 109 end users interviewed, 87 purchased mifepristone+misoprostol and 20 misoprostol-only, while 2 women did not know what drugs they had purchased. Mean self-reported number of weeks of pregnancy was 5.7 weeks. Information provision by pharmacy workers was inadequate (40.4% received none, 8.7% received written information or pictures). A total of 80.5% of mifepristone+misoprostol users were sold the correct regimen versus 9 out of 20 misoprostol-only users. A total of 68.8% did not report experiencing any complications (70.0% misoprostol-only; 69.0% mifepristone+misoprostol users, p=1.0). A total of 94.3% of mifepristone+misoprostol users and 75% of misoprostol-only users reported that they were not pregnant at day 15 (p=.020). However, 7.3% of all users sought additional treatment.
Challenges in assessing outcomes of self-managed menstrual regulation medications purchased from pharmacies must be overcome through further development of this methodology. Interventions are urgently needed to ensure that women have access to correct dosages, accurate information and necessary referrals.
This paper assesses the outcomes of women who self-manage menstrual regulation medications purchased from pharmacies. The methodology requires further development, but our study provides preliminary positive evidence on the safety and effectiveness of self-management despite low information provision from pharmacy workers.
评估对从药店购买米非司酮+米索前列醇或仅购买米索前列醇的女性进行随访,以衡量自行服用月经调节药物的安全性和有效性的可行性。
一项前瞻性队列研究对在孟加拉国从药店购买米非司酮+米索前列醇或仅购买米索前列醇的女性进行了跟踪。参与者由药店工作人员亲自招募或通过药品购买者间接招募。在招募后2周通过电话联系最终用户,进行筛查和访谈。
药店工作人员的研究招募率较低(30%,642名被告知该研究的女性中有109名),但2周随访率较高(87%)。在接受访谈的109名最终用户中,87人购买了米非司酮+米索前列醇,20人仅购买了米索前列醇,而2名女性不知道自己购买了什么药物。自我报告的平均孕周为5.7周。药店工作人员提供的信息不足(40.4%未收到任何信息,8.7%收到书面信息或图片)。米非司酮+米索前列醇使用者中80.5%买到了正确的用药方案,而仅购买米索前列醇的20名使用者中有9人买到了正确方案。共有68.8%的人未报告出现任何并发症(仅使用米索前列醇的为70.0%;使用米非司酮+米索前列醇的为69.0%,p=1.0)。共有94.3%的米非司酮+米索前列醇使用者和75%的仅使用米索前列醇的使用者报告在第15天时未怀孕(p=0.020)。然而,所有使用者中有7.3%寻求了额外治疗。
必须通过进一步完善该方法来克服评估从药店购买的自行管理月经调节药物效果时面临的挑战。迫切需要采取干预措施,以确保女性能够获得正确剂量、准确信息和必要的转诊服务。
本文评估了自行管理从药店购买的月经调节药物的女性的效果。该方法需要进一步完善,但尽管药店工作人员提供的信息较少,我们的研究仍为自我管理的安全性和有效性提供了初步的积极证据。